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ABSTRACT
Zika virus (ZIKV) and Dengue virus (DENV) are flaviviruses that circulate in the same
endemic regions and can co-infect the same individual. While primary infection by DENV leads
to life-long immunity to the infecting serotype, it does not provide immunity to other serotypes.
Moreover, ZIKV and DENV antibodies can be cross-reactive and potentially enhance infection
of the other virus through a process known as antibody-dependent enhancement (ADE). In this
mechanism, antibodies weakly bind the infecting virus and direct virions to immunoglobulin Fc
receptors on macrophages. This promotes viral uptake and infection rather than neutralize the
virus. Due to this mechanism, the typical Ab-based vaccines may not be an appropriate vaccine
design strategy in this context. However, cytotoxic T lymphocyte (CTL) -based vaccines can
protect against infecting viruses without inducing an antibody response. Previously, our lab
designed and tested a ZIKV CTL vaccine. This DNA-based vaccine contained the ubiquitinated,
rearranged sequence for non-structural protein 3 (NS3) of ZIKV and was expressed in pVAX1, a
vector that is FDA-approved for human use. This vaccine induced ZIKV-specific CTLs in mice,
protected mice from viral challenge, and did not significantly induce anti-ZIKV antibodies.
Additionally, this vaccine partially protected against DENV2 infection. To expand this vaccine,
we added ubiquitinated, rearranged NS3 DNA sequences of all 4 DENV serotypes (DENV1-4)
to the existing ZIKV vaccine and immunized mice with our ZIKV-DENV Ub/NS3 constructs.
We hypothesize that our combined ZIKV-DENV Ub/NS3 construct will induce a protective
(non-Ab-mediated) response against both ZIKV and DENV and will expand ZIKV- and DENVspecific CTL populations to provide immunity against these viruses.
v

CHAPTER 1
INTRODUCTION
Zika Virus
Zika virus (ZIKV) is a member of the Flaviviridae virus family. The first case of this
virus was reported in monkeys in Uganda in 1947, and the first human case was reported in
Uganda in 1952 [1]. ZIKV experiences a first major outbreak in 2007 on the Island of Yap in the
Caroline Islands of the Pacific Ocean [2]. Since then, outbreaks have occurred in multiple
countries, such as French Polynesia (2013) and Brazil (2015). Although the WHO declared that
ZIKV was no longer a public health emergency in 2016, it has still remained a serious public
health concern [3]. Main symptoms of ZIKV infection are fever, rash, headache, joint pain,
conjunctivitis, and muscle pain. Symptoms can vary from person-to-person, especially when
considering pregnant women (20% of infected individuals show symptoms while this rises to
65.6% in pregnant women) [4]. Perhaps most notably, ZIKV has been linked to severe birth
defects such as microencephaly and congenital Zika syndrome, the latter of which can include
damage to the back of the eye, congenital hip dysplasia, and brain atrophy in the fetus [5].
ZIKV infection can occur via zoonotic transmission or via person-to-person transmission.
Zoonotic transmission occurs via Aedes aegypti and Aedes albopictus mosquitos, which are the
main vectors for viruses such as Zika, Dengue, West Nile virus, and other viruses, to human
hosts [6]. Human-to-human transmission occurs via two major pathways. First, ZIKV can be
transmitted sexually from one partner to the other. One study showed that following person-to
person transmission, ZIKV RNA was detectable at least 6 months after symptoms onset, well
1
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after ZIKV was undetectable in the bloodstream [7, 8]. Second, ZIKV can be transmitted from
pregnant mother to fetus. During pregnancy, the mother provides antibodies to the fetus, which
cannot produce its own antibodies in the early stages of development [9, 10]. Maternal IgG
antibodies bind to the neonatal Fc receptor on the placenta and cross this barrier to provide
protection for the fetus. During ZIKV infection, the host generates both neutralizing and nonneutralizing antibodies against the virus [11]. Neutralizing antibodies thoroughly bind and coat
the virus particles to prevent the spread of disease, while non-neutralizing antibodies weakly
bind to the virus without inducing a protective effect. Many studies on the antibody response to
ZIKV suggest both neutralizing and non-neutralizing Abs are generated during ZIKV infection
[12]. Therefore, if a pregnant individual is infected with ZIKV and forms non-neutralizing IgGZIKV complexes during infection, these complexes can cross the placenta and deliver ZIKV
particles directly to the fetus to promote infection.
Dengue Virus and ADE
Dengue virus (DENV) is also part of the virus family Flaviviridae and is primarily
transmitted via Aedes mosquitoes. DENV experienced the first recorded outbreak in North
America, Asia, and Africa in 1779. More recent outbreaks have occurred Brazil, Peru, and Belize
(2016) and Pakistan (2019) [13, 14]. As of 2019, the WHO considers it one of
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public health threats. Symptoms of DENV infection are similar to those of ZIKV infection, such
as headaches, nausea, vomiting, rash, pain behind the eyes, and joint or muscle pains [15]. Only
25% of infected individuals display symptoms, which are typically mild flu-like symptoms.
However, severe DENV cases can occur and develop into life-threatening conditions such as
Dengue Shock Syndrome (DSS) or Dengue Hemorrhagic Fever (DHF). These conditions include
severe symptoms like abdominal pain, bleeding from nose or gums, and severe vomiting [15].
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Severe cases of DENV infection are more common in individuals previously infected with
DENV.
DENV consists of four different serotypes (DENV1, DENV2, DENV3, and DENV4)
which have approximately 65% sequence homology across their whole genomes [16]. While
primary infection with DENV leads to life-long immunity against the infecting serotype, it does
not provide immunity to other serotypes [17]. Secondary infection with a different serotype often
leads to DHF [17]. The proposed mechanism for this phenomenon is called antibody-dependent
enhancement of infection (ADE). In this mechanism, pre-existing DENV antibodies against the
previous infecting serotype (i.e. DENV1) weakly recognize and bind to virus particles of the new
infecting serotype (i.e. DENV2, DENV3, or DENV4) [18]. DENV serotypes have high structural
similarity of their external virus particles, which promotes this cross-serotype Ab binding. Rather
than neutralize the virus, these Abs weakly bind the new serotype virus particles and act in a
non-neutralizing way. The resulting DENV-Ab c
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macrophages, which promotes viral uptake and infection of these cells with the new DENV
serotype. Once these viruses enter macrophages (which are the main sites of DENV replication),
they can escape neutralization and cause disease by inhibiting various immune signaling
pathways, such as IL-10 or IFN

e

e [19-21].
ZIKV-DENV Cross-reactivity

Zika virus (ZIKV) and Dengue virus (DENV) co-circulate in the same endemic regions,
and numerous studies have explored the cross-reactivity of ZIKV and DENV antibodies [22-27].
Similar to how ADE occurs for multiple DENV infections, it has been suggested that ZIKV and
DENV Abs enhance infection of the other virus through this mechanism. Since there is
significant homology between the structural regions of ZIKV and DENV, Abs generated in
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response to one virus can weakly recognize and bind the other flavivirus. Rather than be
protective, these Abs direct the virus to immunoglobulin Fc receptors on the surface of
macrophages, which promotes viral uptake and enhances viral infection rather than neutralize the
virus. Therefore, if an individual has been infected with one of these viruses (i.e. DENV), preexisting antibodies can bind to and enhance infection of the other virus (i.e. ZIKV), potentially
resulting in a more severe infection.
Numerous in vitro and in vivo infection studies have demonstrated the cross-reactivity of
ZIKV and DENV Abs. The Screaton group has performed multiple in vitro studies
demonstrating this mechanism with respect to flavivirus infections. Back in 1982, they showed
that anti-DENV2 Abs enhanced DENV infection of U937 cells, which are not normally
permissive to flavivirus infection [19]. After acquiring human sera from individuals previously
infected with DENV2, they added this serum to U937 cells and subsequently added either DENV
or DENV + Yellow Fever Virus (YFV) particles to cells. They found that only cells pre-treated
with anti-DENV2 sera became infected with DENV. Moreover, they discovered these sera were
cross-reactive with YFV and enhanced YFV infection, as they recovered 10x more YFV
particles from cells pre-treated with anti-DENV2 sera. Later in 2016, this same group explored
cross-reactivity between DENV Abs and ZIKV [20]. ZIKV was pre-incubated with pooled
serum from patients 1-2 weeks after they recovered from DENV infection, and these viruses
were used to infect U937 cells. ZIKV pretreated with anti-DENV serum enhanced ZIKV
infection more than 100-fold [20]. Furthermore, this phenomenon was still observed when
patient serum from 6 months-post DENV infection was used. When isolating mAbs from
plasmablasts of DENV-infected patients, they discovered \mAbs against the DENV E protein
recognized and bound to ZIKV. While these studies strongly suggest this ADE phenomenon
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applies to DENV and ZIKV infection, the Suthar group explored this mechanism in a more
physiologically relevant context in 2018. They infected primary placental macrophages from
full-term placentas ex vivo with either ZIKV alone or ZIKV pre-treated with anti-DENV2 mAbs.
When anti-DENV2 antibodies were added, there was significantly higher ZIKV infection in
these cells (10% to >80%) [21]. Moreover, they demonstrated this effect was dependent on IgG
and FcRn interactions, which strongly suggests that IgG Fc-FcRn interactions drive ADE during
DENV and ZIKV infections.
With respect to in vivo studies, the most promising study on DENV-ZIKV ADE was
performed by the Lim group in 2017 [22]. First, they began in vitro experiments to explore this
mechanism. Their work supports previous findings that suggest IgG Fc-FcR interactions drive
ADE [10]. ZIKV was pre-incubated with pooled plasma from DENV patients and used to infect
K562 cells. Pre-treatment with DENV plasma enhanced ZIKV infection, but this was ablated
when IgG-depleted DENV plasma was used. Furthermore, they isolated IgG from DENV patient
plasma and treated it with N-
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ZIKV pre-treated with this modified DENV IgG did not display signs of enhanced ZIKV
infection or ADE. They proposed that ADE must be dependent on IgG Fc-Fc R
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They also demonstrated ADE in vivo. Stat2-/- mice were given pooled plasma from DENVinfected patients, and were infected with ZIKV 2 hours later. Mice that received DENV patient
plasma had 10-fold higher ZIKV RNA levels, exhibited significant weight loss, and succumbed
to infection far more than mice that received control plasma (21.4% vs 93.3%) [22].
Interestingly, they found that DENV patient sera enhanced infection at low injection volumes (2
or 20uL) but was protective against ZIKV infection at higher injection volumes (200uL). Mice
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that received 200uL DENV serum were protected from ZIKV infection, did not experience any
weight loss, and had a 100% survival rate.
Current Landscape of ZIKV and DENV Vaccines
Recently, many efforts have been made to generate ZIKV and DENV vaccines. With
respect to their design, most vaccines target specific types of viral proteins: the structural
proteins and/or the nonstructural (NS) proteins. The three structural proteins (C, prM, and E)
form the outside of the virus particle and enclose viral RNA [23]. These proteins also facilitate
viral entry by binding to cell surface factors in the host to promote infection. The seven nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5) are translated as one large
polyprotein, and they aid in viral RNA replication and polyprotein processing [24]. NS3 is
particularly important, as it contains both helicase and protease domains joined by a small linker
region. The NS3 helicase domain intimately interacts with polymerase and is a critical
component of viral replication [24]. Furthermore, the NS3 protease domain cleaves the large NS
polypeptide into its resulting seven NS proteins and renders these proteins to be functional.
Many vaccines are designed to induce neutralizing Abs against these proteins. With respect to
ZIKV and DENV vaccines, research groups have explored many different design strategies.
These include vaccines based on live attenuated and inactivated viruses, recombinant viral
vectors, chimeric viruses, DNA or mRNA-based constructs, and even protein/peptide vaccines.
A decent number of ZIKV and DENV vaccines are DNA-based. These vaccines consist of a
plasmid that encodes for specific viral proteins. Once in the host, these plasmids are transcribed
and translated to generate an immunizing protein. DNA vaccine design strategies are popular,
since these vaccines can stably express the encoded proteins over time (making it more likely to
induce CTLs), are shown to be safe for the recipient [25]. Many nucleic acid-based and protein-
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based ZIKV vaccines encode for the two structural proteins prM and E, since these elements are
responsible for receptor binding and viral fusion during infection [26]. One group recently
generated a ZIKV vaccine called ZIKV-80E which co-expresses truncated versions of these
proteins (last 34 aa residues of prM + first 403 aa residues of E) in the pPICZ-A plasmid [26].
When expressed in P. pastoris, these proteins formed highly immunogenic VLPs that elicited a
neutralizing Ab response. Importantly, the Abs generated from ZIKV-80E did not exhibit any
cross-reactivity to recombinant DENV E proteins (>90% specificity for ZIKV E). With respect
to DENV, numerous vaccines candidates follow a similar design. One group designed a DENV3based vaccine very similar to the ZIKV one mentioned above. This group expressed the DENV3
prM and E protein in the DNA vector pVAX1, which is approved for human use. Results from
immunization experiments show that in mice, three doses of this vaccine were sufficient to
induce antigen-specific T cell responses and neutralizing Abs [27]. Additionally, it provided
immunity against the other three DENV serotypes, and this protection persisted at 12 months
post vaccination.
Aside from vaccines that target structural proteins, some groups have shifted their focus
towards designing vaccines that target the NS proteins [24, 28]. Since NS proteins are critical
for viral replication and viral protein processing, they are indispensable to viral survival. This
makes them attractive targets for vaccine design, since they are less prone to mutations over
time. The proteins NS1, NS3, and NS5 specifically have made increasingly more appearances in
new ZIKV and DENV vaccines. DENV NS1 contains MHC I and MHC II epitopes that are
prominent targets for T cells, ZIKV/DENV NS3 are the most immunodominant targets for
cellular responses, and ZIKV/DENV NS5 is the most conserved NS protein across DENV
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serotypes [24]. These proteins are attractive targets for vaccine design due to their highly
conserved nature and importance in viral replication.
Multiple ZIKV and DENV vaccines have been designed using the sequences of NS1,
NS3, and/or NS5 proteins, and these have proven to be quite successful and immunogenic. For
example, one ZIKV NS3-based vaccine induced a protective CD8+-mediated T cell response.
Vaccinated mice were able to control viral burden, and murine fetuses experienced completely
normal development [29]. More importantly, they did not induce any Abs, which can potentially
enhance ADE with respect to DENV exposure. DENV vaccines have been generated using
recombinant NS1, NS3, and/or NS5 proteins. One DENV vaccine that used recombinant NS1
(modified so the C-terminal epitopes were replaced with those of Japanese encephalitis virus)
and NS3 potently induced antigen-specific CD4+ and CD8+ T cells [28]. Another DENV vaccine
that used recombinant DENV2 NS5 was not only recognized by serum from DENV-infected
patients for all four serotypes, but also induced neutralizing NS5 Abs, IFN-g and TNFaproducing T cells, and protected mice from lethal DENV2 challenge [30]. While more research
needs to be done to thoroughly explore the efficacy of these vaccines, they provide a promising
starting point for flavivirus vaccine design strategy.
Notable Flavivirus Vaccines Undergoing Clinical Trials
Currently, there are almost no commercially available or approved vaccines for these
viruses. However, there has been significant progress in vaccine development in recent years.
Two notable ZIKV vaccines have made their way into clinical trials. In 2017, a Phase 2 clinical
trial began for a DNA ZIKV vaccine VRC 705 [31]. This plasmid-based vaccine encodes for the
wild type prM and E structural proteins from ZIKV strain H/PF/2013. This study immunized
almost 2400 participants via intramuscular injection. Although Phase 2 results have not been
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released yet, Phase 1 results from this trial were quite promising. Over 60% of participants
induced neutralizing Abs, and had significantly induced CD4 and CD8 T cell responses
(indicated by peptide stimulation and intracellular cytokine staining) following vaccination [32].
In 2018, a P
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chimeric live attenuated vaccine expresses ZIKV surface proteins in a DENV4 backbone. Upon
last update, it showed promising results in Rhesus macaques and had begun human testing [32].
Phase 2 testing was expected to take 1 year, and the human data from this clinical trial is not yet
available.
With respect to DENV, perhaps the most well-known vaccine is Dengvaxia. This live
attenuated tetravalent vaccine from Sanofi Pasteur consists of a YFV backbone with the prM and
E proteins substituted by these same DENV proteins from all four serotypes [33]. Dengvaxia was
approved for use in the US by the FDA in 2019, and is specifically recommended for individuals
9 to 16 years old who live in common areas of DENV exposure and who have been previously
infected by DENV [34] . One of the major limitations and concerns of this vaccine is that it
seems to act like a first DENV infection for previously uninfected individuals [33]. Upon
subsequent DENV infection, vaccinated individuals can contract life-threatening severe DENV
disease. In 2017, this was exactly what occurred in the Philippines. Over 700,000 individuals
were vaccinated with Dengvaxia, and soon, numerous children were dying from complications
associated with the vaccine [33]. This situation raised awareness in the scientific community
regarding just how carefully researchers need to design such vaccines.
Two notable DENV vaccines have begun clinical trials. The first comes from the abovementioned Dr. Stephen Whitehead, PhD. His laboratory produced the DENV vaccine TV003, a
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live attenuated tetravalent admixture with monovalent DENV vaccines targeting all 4 virus
serotypes [35]. DENV
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untranslated region of each serotype. Previously, the Buntantan Institute in Brazil licensed the
four vaccine components and slightly modified the composition of this vaccine to create
Buntantan-DV [36]. Whereas TV003 is a single-dose frozen admixture, Buntantan-DV is
lyophilized ten-dose vial vaccine. Both vaccines were tested in DENV-naïve and DENV-exposed
individuals in Brazil. The vaccines are currently in Phase 3 clinical trials. These trials showed
that Buntantan-DV immunized participants displayed an overall 65% (DENV-naïve) and 55%
(DENV-exposed) tetravalent Ab response [36]. These individuals displayed significant induction
of IFN-g-producing CD8+ T cells after stimulation with viral peptides. They observed similar
results upon immunizing with TV003, which led the group to conclude that despite their
different formulation, these two are analogous vaccines. However, regardless of seropositive
status, both DENV-naive and DENV-exposed individuals experienced adverse physical effects
such as rashes (65% and 45% of participants), myalgia (20% and 25%) and even leukopenia
(12% and 8%) [36].
The second DENV vaccine in clinical trials, TAK-003, originally comes from a Mahidol
University in Bangkok, but is sponsored by Inviragen and Takeda. TAK-003 is a live attenuated
tetravalent vaccine, and consists of a DENV2 backbone where the prM and E proteins of
DENV2 strain PDK53 are substituted by the same proteins from DENV1, DENV3, and DENV4
[37]. Phase 1 and 2 of clinical trials showed this vaccine elicited significant neutralizing Ab
responses against all four DENV serotypes in both DENV seropositive and seronegative
individuals [37]. These titers persisted for 48 months post vaccination. The vaccine was currently
in Phase 3 clinical trials, where vaccine efficacy for all four serotypes was found to be 80.2%,
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with the highest responses against DENV1 and DENV2 [38]. At this point in time, there are no
combined ZIKV-DENV vaccines in clinical trials. However, Dr. Whitehead has stated he would
like to combine the ZIKV and DENV vaccines from his lab to form such a vaccine, and
hopefully have it tested in clinical trials in the near future.
Although these mentioned flavivirus vaccines yield promising results, there are still
numerous concerns over their efficacy and safety. First, the previously mentioned DENV and
ZIKV vaccines mainly provide protection by eliciting an Ab response. While neutralizing Abs
can indeed be protective against multiple serotypes of DENV, there is an incredibly thin line
between what level of Ab is considered protective and what level promotes ADE. Moreover, the
level of vaccine-induced anti-DENV Abs for each serotype varies widely from person to person,
so there is considerable variability and inconsistency in the level of protection offered by these
vaccines. The vaccine may significantly induce neutralizing Abs against one serotype (i.e.
DENV1), but it may not induce a protective level against a different serotype, potentially
predisposing the recipient to ADE. Second, there is a notable lack of knowledge of which viral
epitopes induce neutralizing vs ADE-enhancing Abs. While peptide-stimulation studies are being
performed in transgenic mice [39] and prediction software is being used to discover protective
human anti-DENV and anti-ZIKV epitopes in structural and non-structural proteins [40], more
work needs to be done to evaluate whether these epitopes are actually protective in a real human
infection. Finally, many of these vaccines induce significant adverse physical reactions in the
host, such as rash, fever, and even vomiting [36], which are not pleasant for the participants
involved in clinical trials. Some of these reactions can be problematic for individuals long-term,
so effort must be taken to dampen these effects as much as possible.
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CTL-Inducing ZIKV and DENV Vaccines
Many groups have demonstrated significant cross-reactivity of anti-ZIKV and antiDENV Abs and their ability to induce ADE [22-28]. As mentioned above, ADE is particularly
problematic with ZIKV and DENV infections. This makes designing ZIKV and DENV vaccines
a challenge, since the goal of many vaccines is to induce an Ab response. Therefore, an Abinducing vaccine may not be appropriate for either virus. However, vaccines that induce virusspecific CD8+ cytotoxic T cells (CTLs) can be beneficial at inducing immunity against these
viruses. Such vaccines are designed to promote a CTL response against the virus in question.
This method circumvents an Ab response while still inducing protective immunity in the host. As
mentioned above, some ZIKV and DENV vaccines based on NS proteins can potently induce
CTLs [28, 30]. Previous CTL epitope data for ZIKV and DENV shows that NS3 and NS5
contain the most CTL epitopes [41], which makes them primary targets for a CTL-inducing
vaccine. While just a limited number of mouse and/or human ZIKV and DENV CTL epitopes
have been tested and experimentally confirmed by in vivo experiments [41], epitope software
like NetCTLPan can be used to predict possible CTL epitopes. These tools provide researchers
with plausible starting points for developing CTL-based ZIKV and DENV vaccines.

CHAPTER 2
MATERIALS AND METHODS
Rearranged Ub/NS3 Gene Design and Ligation into pVAX1
Both DENV-ZIKV NS3 plasmids were designed using the same rearrangement and
ubiquitination strategy. These five viral NS3 sequences contain more DNA than can fit inside
our pseudoviruses (~7.5 kb), so they were split across two plasmids. Although we do not plan to
use pseudoviruses for our experiments, we divided the constructs this way so we could possibly
package them in virus-like particles (VLPs) for more effective delivery in the future. NS3
sequences from the following viral strains were used: DENV1 strain ThD1_0102_01 (Accession
Number: AY732479), DENV2 strain BR64022/2002 (Accession Number: AF489932), DENV3
strain H87 (Accession Number: KU050695), DENV4 strain G11337/2012 (Accession Number:
JF262783), and ZIKV strain RGN/2016 (Accession Number: KU527068). Each viral NS3
sequence was split into three parts. 30 nucleotide bases were added as overlaps to these
fragments to preserve any CTL epitopes that may have been lost due to rearrangement (Fig. 1a).
This rearrangement was performed for all viruses except DENV3. DENV3 shares a homologous
region with DENV1, and a separate homologous region with DENV2. These two segments were
both removed from DENV3 before this gene was split into two fragments over both plasmids.
This split was done in two parts solely due to VLP size limitations. Overlaps of 30nt were added
to the end of Fragment 1 and beginning of Fragment 2 to preserve potential CTL epitopes (Fig.
1b). Subsequently, these five NS3 sequences were split across two plasmids (P1 and P2) as
follows: P1 contained ZIKV F3, F2, F1 - DENV1 F3, F2, F1 - DENV3 F1. P2 contained DENV3
13
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F2 - DENV2 F3, F2, F1 - DENV4 F3, F2, F1. Within each plasmid, all the NS3 fragments exist
in the same reading frame and will be translated as one large polyprotein. Next, the sequence
encoding for human/mouse ubiquitin monomer (Ub) was obtained (Accession Number:
P0CG50). Gly76 was modified to Ala76 to increase stability of the Ub/NS3 complex and
promote degradation of the polyprotein. The Ub sequence was inserted upstream of the
rearranged NS3 sequences. Upstream of this combined Ub/NS3 sequence, the human Kozak
sequence was inserted to ensure efficient translation of the rearranged polyprotein. Downstream
of the re-arranged Ub/NS3 sequences, a stop codon was added. Our two Ub/NS3 DNA
sequences were both synthesized and ligated into pVAX1 through the Genscript Gene Synthesis
Program.
Bacterial Transformation
Top10 E. coli (ThermoFisher) were removed from the -80oC freezer and thawed on ice
for 25 minutes. Ligated Ub/NS3/pVAX1 were introduced to E. coli and incubated on ice for 30
minutes. Bacteria were heat shocked in a 42oC water bath for 30 seconds and placed back on ice
for 2 minutes to recover. 950uL LB was added to the E. coli and cells were shaken for 1.5-2 hrs
at 37oC. Afterward, cells were plated on LB+Kanamycin agar plates, inverted, and incubated
overnight at 37oC. The next day, colonies were selected and inoculated into 1 mL LB+Kan and
shaken overnight. Minipreps were performed using the Qiagen QIAprep Spin Miniprep Kit.
Plasmids were digested with EcoRI/XbaI (for P1) or HindIII/NotI (P2) to confirm correct insert
size. Megapreps were performed using the Qiagen Plasmid Mega Kit to produce sufficient
amounts of both plasmids for mouse vaccination experiments.
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Plasmid Transfection
293T cells were cultured in complete DMEM and split upon reaching 90% confluence
(every 2-3 days. For transformation, cells were seeded in serum-free DMEM at 1 million
cells/well in a 6 well cell culture plate. Cells were transfected overnight with either 1ug DENVZIKV Ub/NS3 Plasmid 1 (ZIKV, DENV1, and half of DENV2) or Plasmid 2 (DENV2, DENV4,
and half of DENV3) at a 1:1 ratio of DNA:PEI. The following morning, transfection media was
replaced with complete DMEM, and cells recovered for 24h . Then, 50 M

o eo ome inhibi o

(MG132) was added to cell culture medium overnight. Cells were collected the following
morning and prepared for western blot.
SDS-PAGE Gel and Western Blot
293T cells were cultured, transfected, and treated with proteasome inhibitor as described
above. After treatment with MG132, cells were collected into Eppendorf tubes and spun down at
1250rpm for 5 minutes. Cell pellets were resuspended in 40uL SDS and subsequently boiled for
10 minutes in a 100oC heat block. 20uL proteinase K was added directly after. 20uL of sample
was loaded onto a 10% resolving SDS-PAGE gel and ran at 15mA for about 1hr. Bands were
transferred to a nitrocellulose membrane using the Invitrogen iBlot system (processed at 20V for
7.5 minutes). After transfer, the membrane was blocked with 5% milk-TBST at RT for 1hr. The
membrane was then washed 3x with TBST to remove blocking solution. Primary Abs were
diluted 1:1000 in 5% milk-TBST (anti-ZIKV NS3 for P1, anti-DENV2 NS3 for P2) and
incubated at RT for 2 hrs. Membrane was washed as previously described. Secondary HRPconjugated Abs were diluted 1:5000 in 5% milk-TBST (anti-rabbit IgG for P1, anti-mouse IgG
for P2) and incubated at RT for 1hr. Membrane was washed as previously described. To develop
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the blot, ThermoFisher West Pico Plus solution was added to the membrane and incubated at RT
for 15 minutes. Bands were visualized using the Protein Simple machine.
Vaccine Administration
In our first vaccine experiment, 4-6 wk female Balb/c mice were used. 3 females were
used per experiment group. Mice were split into two treatment groups: PBS only and 5ug P1 +
5ug P2 + 20ug Gardiquimod. All mice received hind quadriceps injections of 50uL total, which
is appropriate for the size of these animals. Mice were first injected with respective compounds
on Day 0, and then boosted with the same compounds two weeks after initial injection (Day 14).
Mice were sacrificed four weeks post initial injection (Day 28), and at this point, spleens were
collected to assess the DENV- and ZIKV-specific splenocyte response.
In the second vaccine experiment, 4-6 wk male and female Balb/c mice were used. 6
male and 6 female mice were used per experiment group. Mice were split into three treatment
groups: PBS only, 20ug Gardiquimod only, and 10ug P1 + 10ug P2 + 20ug Gardiquimod. All
mice received hind quadriceps injections of 50uL total. Mice were injected with respective
compounds on Day 0, and then boosted with the same compounds three weeks after initial
injection (Day 21). Mice were sacrificed two weeks after boost injections (Day 35), and at this
point, spleens were collected to assess the DENV- and ZIKV-specific splenocyte response.
Splenocyte Harvesting
Mice were euthanized via CO2 asphyxiation followed by cervical dislocation, and spleens
were removed. Splenocytes were harvested by crushing spleens between glass slides over a petri
dish containing RPMI-1640 media (supplemented with 10% FBS, 1% pen/strep, and 1%
HEPES). Slides were rinsed off with media to collect as many cells as possible, and cells were
filtered over mesh to remove debris. Cells were spun down in a conical tube at 1250 rpm for 5

17
minutes and supernatant was discarded. Then, cells were suspended in 500uL ACK lysis buffer
for 1 minute to lyse red blood cells. 10 mL RPMI-1640 was added to the tube to inactivate lysis
buffer, and cells were spun down again. Supernatant was discarded, and splenocytes were
resuspended in RPMI-1640 to obtain cell counts before plating into Elispot plates.
Splenocyte Stimulation and Elispot Assay
In the first vaccination experiment, splenocytes were seeded in 96-well Elispot plates
(Mabtech) at a concentration of 200,000 cells/well in 100uL of RPMI-1640. They were then
assessed for production of IFN-g, TNF-a, and IL-2, which are known CTL cytokines. Separate
Elispot plates were used for each cytokine. Prior to splenocyte addition, plates were first washed
4x with 200uL of sterile PBS per well and incubated at RT with 200uL of media containing 10%
serum for 30 mins. Cells were added and adhered to plates for 2 hrs prior to peptide stimulation.
Two CTL-specific ZIKV and DENV NS3 epitopes have been identified in literature:
GYISTRVEM and GYISTRVGM. The epitope GYISTRVEM is present in ZIKV, DENV2, and
DENV4 NS3, while the epitope GYISTRVGM is present in DENV1 and DENV3 NS3. ZIKV
and DENV peptide arrays were acquired from BEI Resources, and peptides from these kits that
contain the above epitopes were used for splenocyte stimulation. Peptide 41 from the DENV2
array (GYISTRVEM), and Peptide 52 from the DENV1/3 array (GYISTRVGM) were used. The
following conditions were tested in triplicate for each mouse: media only (negative control),
0.5ug peptide, 1ug peptide, and 1ug Concanavalin A (positive control). 100uL of these
compounds was added to the appropriate wells and incubated overnight at 37oC. Following
peptide stimulation, all plates were washed/stained for CTL-specific cytokines using the protocol
below: media/stimulation mixtures were dumped from wells, and plates were washed 5x with
200uL sterile PBS per well. Detection antibody was diluted to 0.5ug/mL (TNF-a) or 1ug/mL
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(IFN-g and IL-2) in PBS containing 0.5% FBS. 100uL was added per well, and this incubated at
RT for 2 hrs. Plates were washed as described above. Streptavidin-ALP was diluted 1:1000 in
PBS-0.5% FBS. 100uL was added per well, and this was incubated at RT for 1 hr. Plates were
washed as described above. The ready-to-use substrate solution (BCIP/NBT-plus) was passed
through a 45um filter, and 100uL was added per well to develop spots for approximately 15-20
minutes. Plates were washed with tap water and dried completely before spots were counted.
Positive control wells were counted up to 200 spots.
In the second vaccination experiment, splenocytes were seeded in 96-well ELISpot plates
(BD Biosciences) at a concentration of 200,000 cells/well in 100uL of RPMI-1640 to assess for
production of IFN-g and TNF-a. Separate Elispot plates were used for each cytokine. First,
plated were coated with antibody for the respective cytokines (IFN-g or TNFa). Abs were diluted
in 100uL PBS and added to plate wells. Plates were incubated at 4oC overnight. Coating
antibody was discarded, and wells were washed with 200uL blocking solution (RPMI-1640 +
10%FBS + 1% Pen/Strep). Blocking solution was discarded, and an additional 200uL of this
solution was added to wells and incubated for 2hrs at RT. Splenocytes were stimulated by adding
various peptides/stimuli to wells. The following conditions were tested in triplicate for each
mouse: cells only (negative control), 1ug virus-specific peptide, and PMA/ionomycin (positive
control). DENV-specific peptides were used from the DENV arrays obtained from BEI
Resources. Since previous experiments from the lab show our rearrangement of NS3 induced
ZIKV-specific CTLs, this experiment focused on discerning whether these constructs induced
anti-DENV immune responses. The following NS3 peptides were used for splenocyte
stimulation: Peptide 28 from the DENV1 array (TYVSAIAQA epitope), Peptide 74 from the
DENV2 array (SPGTSGSPI epitope), Peptide 30 from the DENV3 array (IFQTTTGEI epitope),
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and Peptide 46 from the DENV4 array (CHATFTTRL epitope). 1ug of peptide or
PMA/ionomycin was added to wells in 100uL RPMI-1640. Splenocytes were collected from
mice as previously described and seeded at a density of 200,000 cells per well in 100uL RPMI1640. Elispot plates were incubated at 37oC overnight (approximately 18hrs). The following day,
cells and peptides/stimuli were discarded, and wells were washed 3x with Wash Buffer (1x PBS
+ 0.05% Tween-20). Biotinylated detection Ab was diluted 1:250 in 100uL RPMI-1640 and
added to wells to incubate for 2hrs at RT. This solution was discarded, and wells were washed 3x
with 200uL Wash Buffer. Streptavidin-HRP secondary Abs were diluted 1:250 in 100uL RPMI
and incubated for 1hr at RT. Wells were then washed 2x with PBS. To develop wells, 30uL of
TMB substrate (Sigma) was added to each well. Wells developed for approximately 5-15
minutes. Plates were washed in tap water to stop the reaction, and plates were left to dry
overnight before spots were counted.
Elispot CTL Epitope Prediction
As stated previously, few CTL epitopes for ZIKV and DENV have been confirmed in
literature [41]. The confirmed epitopes are shared across multiple DENV serotypes and even
with ZIKV. Since we wanted to evaluate the CTL response to each of the five viruses
individually, we required epitope sequences that were unique to each virus. Therefore, we
utilized epitope prediction software (NetCTLPan) to predict H2-Kd epitopes for Balb/c mice for
ZIKV and DENV1-4. The peptides used in the second ELISpot were predicted to be the most
likely virus-specific peptides presented on MHCI.
Statistical Analysis
All data shown for the Elispot experiments was analyzed using a two-way ANOVA or
S den
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CHAPTER 3
ASSEMBLY AND CHARACTERIZATION OF THE REARRANGED UB/NS3 GENE
Introduction
DENV consists of four different serotypes (DENV1, DENV2, DENV3, and DENV4)
which share approximately 65% sequence homology across their whole genomes, while DENV
and ZIKV are approximately 55% similar [16, 42]. ZIKV and DENV co-circulate in the same
endemic regions, and numerous studies have explored the cross-reactivity of ZIKV and DENV
antibodies [22-27]. Similar to how ADE occurs for multiple DENV infections, it has been
suggested that ZIKV and DENV Abs enhance infection of the other virus through this
mechanism. Since there is significant homology between the structural outer virus proteins of
ZIKV and DENV, Abs generated in response to one virus can weakly recognize and bind the
other flavivirus. Rather than be protective, these Abs direct the virus to immunoglobulin Fc
receptors on the surface of macrophages. This promotes viral uptake and enhances infection.
Therefore, if an individual has been infected with one of these viruses (i.e. DENV), these preexisting antibodies can bind to and enhance infection of the other virus (i.e. ZIKV), potentially
resulting in a more severe infection. It has been found that human monoclonal antibodies from
DENV-infected patients cross-react with ZIKV but do not neutralize the virus [20]. Due to crossreactivity and ADE not only within DENV serotypes, but also between DENV and ZIKV,
vaccine design is a big challenge. Previous research as mentioned above suggests an Abmediated vaccine would likely not be as protective as hoped. However, vaccines that induce
CTLs are a promising strategy since they confer protection to the host while circumventing the
20
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need for an Ab response. While live attenuated or protein-based vaccine are popular strategies
for with DENV and ZIKV vaccines, DNA-based vaccines have gained popularity in this field
largely for their stability, their safety, and their ability to induce CTLs [25]. One aspect that can
help generate CTLs is encoding for a ubiquitinated protein. Previously, it has been shown that
ubiquitination of a viral protein enhances CTL production without inducing an Ab response [43].
The goal of our method is to design a plasmid encoding for a ubiquitin-tagged protein, as this
will immediately be targeted to the proteasome for degradation. Once degraded, the resulting
peptides will be transported through the TAP complex of the ER for loading onto MHCI
molecules. These complexes are then shuttled to the cell surface where they can engage with the
T cell receptor and CD8 on CTLs to activate them [44, 45].
For our constructs, we rearranged the NS3 sequences of the DENV and ZIKV so they
would become nonfunctional and unstable, yet still retain all potential CTL epitopes. The design
for these constructs can be found in Figure 1. Briefly, each gene was split into three parts
containing 10 aa overhangs to preserve any potential CTL epitopes. Due to size limitations, these
sequences were split across two plasmids. For each plasmid, the ORF for a ubiquitin monomer
was placed upstream of the rearranged NS3 sequences. This Ub sequence will target the protein
to the proteasome for immediate degradation, which will help produce MHCI antigens and
subsequently, DENV- and ZIKV-specific CTLs.
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Figure 1. Detailed Schematic of Ub/NS3 ZIKV-DENV Plasmid Design. Above is the design
for our Plasmid 1 (P1) and Plasmid 2 (P2) constructs. a) Upstream of each NS3 sequence, we
placed the sequence for the ubiquitin monomer with a G76 to A76 mutation to enhance stability.
Each NS3 sequence aside from DENV3 was rearranged in the way depicted on the right. NS3
genes for ZIKV and DENV were split into three parts, each with 10 aa overhangs at the
beginning and end. One region of DENV3 was completely removed, as it had 100% homology to
sequence in DENV1 and DENV2. DENV3 was then split into two fragments across both
plasmids to adhere to VLP size restrictions. b) Due to VLP size restrictions, we could only fit
approximately 7.5kb into each vector. Therefore, we created two plasmids (Plasmid 1 and
Plasmid 2), which contain the rearranged NS3 sequences of ZIKV and DENV1-4.
Assembly of Vaccine Plasmid
When ordering the above DENV-ZIKV Ub/NS3 constructs, Genscript kindly performed
the ligation into pVAX1 and subsequent cloning into E. coli. Lyophilized plasmid and bacterial
stabs were sent upon completion of the product. Transformed bacteria were streaked out from the
bacterial stab onto LB + Kanamycin plates, and colonies were picked for bacterial megapreps to
generate enough of our plasmids for animal experiments. Plasmids 1 and 2 were flanked by
unique RE sites in pVAX (EcoRI and XbaI for P1, HindIII and NotI for P2) and were digested to
confirm correct insert size (data not shown).
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Western Blot Analysis of Protein Expression
With respect to these constructs, there can be difficulty in expressing not only a
rearranged protein, but also one that is inherently ubiquitinated. A translated protein must pass
through the proper folding pathways and checkpoints in the ER. These processes are monitored
by intracellular pathways of a system called the Unfolded Protein Response. The primary job of
this system is to prevent misfolded proteins from leaving the ER, as the improper release of such
proteins can have detrimental consequences for the host. When misfolded proteins are detected,
they are shuttled to the proteasome for degradation [46]. In the context of our vaccine however,
activation of this unfolded protein response may actually be beneficial. To generate a T cell
repertoire, proteins must be degraded into 8-11 aa long epitopes to generate T cell antigens [46].
Once epitopes have been generated, they are loaded onto MHCI molecules in the ER before
being shuttled to the cell surface, where they can potentially activate CTLs. With respect to the
encoded Ub in our constructs, this Ub could enhance degradation of the protein so much that it
may not be visible via Western Blot to confirm proper expression. This can be overcome by
using a proteasome inhibitor, such as MG132. This compound acts on the enzymatic sites of the
proteasome to inhibit their function [46]. After cell transfection and treatment with MG132, one
would expect to observe faint bands of approximately 180 kDa in transfected 293T cells without
MG132 treatment, and much stronger bands in transfected 293T cells that have been treated with
this proteasome inhibitor.
To confirm protein expression from our constructs, 1 million 293T cells were transfected
in serum-free media with 5ug of either P1 or P2 at a 1:1 ratio of DNA:PEI. 250uL each of DNA
and PEI were prepared in separate tubes and then gently mixed with a pipette immediately before
adding to wells. Mixtures were added dropwise to wells to transfect cells overnight. Complete
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media was added the next morning to help cells to recover. 24hrs post recovery, 50uM MG132
was added wells and incubated overnight. Samples were then collected, and a Western blot was
performed to visualize the rearranged Ub/NS3 proteins from P1 and P2. If these Ub/NS3 proteins
are expressed, then we should observe bands only in 293T cells transfected with our constructs..
In our Western blot for P1, there appears to be a non-specific band in the untransfected
cell wells right underneath the band representing our rearranged NS3 protein (Fig. 2). The blot
for P2 shows no additional bands apart from our expected NS3 bands. In the blot for P1, we
observe similar protein levels in transfected cells regardless of the presence or absence of
MG132 inhibitor. This could be due to a timing factor. We added inhibitor 24 hrs posttransfection, which may not be enough time for our construct to be both translated and
subsequently directed to the proteasome for degradation. Perhaps addition of MG132 at a later
timepoint after transfection (36 or 73 hrs) would show greater difference between our two
samples, namely that we would see a stronger band (i.e. more protein) in cells treated with
inhibitor, and a minimal if any band in transfected cells without inhibitor. In the blot for P2, there
appears to be slightly more protein in transfected cells with MG132 inhibitor as opposed to those
that were untreated, although this has not been experimentally quantified. Based off these blots,
we feel confident that our Ub/NS3 constructs express their respective proteins.
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Figure 2. Western Blot to Confirm Protein Expression from Rearranged Ub/NS3
Constructs. 1 million 293T cells were transfected with either P1 or P2 overnight at a 1:1 ratio of
DNA:PEI. Cells recovered for 24 hrs post transfection, and then 50ug of MG132 was added to
wells overnight to inhibit the proteasome. The following morning, samples were collected, an
SDS-PAGE gel was done, and a Western Blot was performed to blot for either the ZIKV NS3
protein (P1) or the DENV2 NS3 protein (P2).
Discussion
The goal of our study was to design a combined ZIKV-DENV vaccine that would confer
protection through virus-specific CTLs. Plasmids were designed by splitting the NS3 sequences
of ZIKV and DENV1-4 into 3 parts and then rearranging them to disrupt protein function. 10aa
overhangs were added to the beginning and end of each fragment to preserve possible CTL
epitopes. These sequences were preceded by an upstream Ub sequence to aid in degradation and
generation of CTL epitopes. Ubiquitin is used to tag proteins that will be shuttled to the
proteasome for degradation. This molecule uses its G76 residue to covalently bind to a K48
residue on the target protein [43]. After this initial step, additional ubiquitin molecules continue
binding to lysine residues to generate a large ubiquitin chain. Then, the polyubiquitinated protein
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is directed to the proteasome for degradation [43]. However, previous papers have shown that the
G76 residue can actually be cleaved from Ub/NS3 constructs, meaning they do not actually
remain ubiquitinated [47, 48]. To prevent this issue, some groups have shown that a G76 to A76
mutation reduces this cleavage. Therefore, we added this same mutation into our Ub sequence in
both our P1 and P2 constructs. This design method ensures that every protein generated from our
P1 and P2 constructs will be inherently ubiquitinated, and remain that way once expressed in
cells, which will help generate ZIKV- and DENV-specific CTLs.
After obtaining our plasmids via megapreps, we needed to confirm proper protein
expression. 1ug of either P1 or P2 was transfected into 293T cells overnight, and 24 hours posttransfection, cells were treated with 50ug MG132 proteasome inhibitor. This step was necessary,
as our proteins were ubiquitinated and also rearranged in a way that facilitated their rapid
degradation. Once samples were collected, run on an SDS-PAGE gel, and blotted for proteins of
interest, we observed bands of the appropriate size (~180kDa) in transfected cells. Although not
quantified, it appears there are stronger bands in our P2-transfected sample treated with
proteasome inhibitor compared to cells that were not treated with MG132. We should expect this
same trend with P1 protein expression, however we see relatively similar amounts of the protein
in both conditions. Although we do not see as intense differences between inhibitor-treated and
non-treated transfected cells as we expect, our blot show that our rearranged Ub/NS3 constructs
successfully express their encoded proteins.

CHAPTER 4
IMMUNIZATION AND IN VIVO DETECTION OF NS3-SPECIFIC CD8+ T CELL
REPERTOIRE
Introduction
As mentioned previously, generating an Ab response to ZIKV and DENV is not the most
effective method to induce short or long-term immunity to these viruses because of ADE.
Instead, a more promising approach is to induce virus-specific CTLs that can immediately
respond to infection and control viral proliferation. With respect to specific mouse models for
ZIKV and DENV infection, immunocompetent mice are not natural hosts for these viruses.
However, it has been shown that mice with deficiencies in type I interferon signaling are more
susceptible to flaviviruses [49]. Two prominent models are Ifnar1-/- and Stat2-/- mice. Mice
completely lacking Ifnar1 developed severe ZIKV disease and succumbed to infection [50, 51].
While this model can be useful, it does induce quite severe infection. Stat2-/- mice however are a
much milder model for flavivirus infection. The Bardina group used this model in their ZIKV
challenge experiment. They administered plasma from DENV-positive patients to mice and
subsequently infected Stat2-/- mice with ZIKV. Mouse survival significantly dropped when mice
were given DENV plasma (20% survival vs 90% with control plasma) [52]. Prior to using any of
the above animal models for infection and vaccination experiments with our DENV-ZIKV NS3
constructs, it is first necessary to demonstrate whether our P1 and P2 plasmids induce virus
specific CTLs in control mice.
27
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Immunization of BALB/C Mice with Naked DNA Supplemented with Adjuvant
For our first mouse vaccination experiment, we immunized 3 Balb/c female mice with
both our P1 and P2 plasmids. Mice received 5ug each of P1 and P2, as well as 20 ug
Gardiquimod adjuvant. All mice received hind quadriceps injections of 50uL total. Mice were
first injected on Day 0, and then boosted with the same compounds two weeks after initial
injection (Day 14). Mice were sacrificed four weeks post initial injection (Day 28), and at this
point, spleens were collected to assess the DENV and ZIKV-specific splenocyte response. For
the second mouse experiment, we immunized 6 Balb/c male and female mice per group with the
following vaccine mixtures: 10ug P1 + 10ug P2 + 20ug adjuvant, 20ug adjuvant only, or PBS.
Mice were first injected on Day 0, and then boosted with the same compounds three weeks after
initial injection (Day 21). Mice were sacrificed five weeks post initial injection (Day 35), and at
this point, spleens were collected to assess the DENV and ZIKV-specific splenocyte response.
Many attempts have been made to enhance the immunogenicity of DNA vaccines. One of
the methods mentioned briefly before is virus-like particles, or VLPs. These are formed when
capsid proteins from certain viruses are expressed within a cell. For example, the L1 capsid
protein of HPV-16 has been shown to assemble into VLPs when expressed in eukaryotic cells
[53, 54]. These particles can be disassembled using reducing agents and reassembled to package
plasmids for delivery to cells, and at this point, the particle is considered a pseudovirus (PV).
Groups have shown that immunization with PV induces stronger CTL responses than
immunization with naked DNA encoding the same epitope [55]. Another method is to administer
adjuvants alongside the plasmid. These molecules typically activate receptors of the innate
immune system known as Toll-like receptors (TLRs). The immune system uses these receptors
to sense pathogens and induce appropriate immune responses against them. Plasmid DNA
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immunogenicity can be enhanced through adding CpG motifs, which are common in bacterial
genomes signatures that readily activate TLRs. The ubiquitin monomer upstream of our
rearranged NS3 sequence introduces approximately 12 CpG motifs, which are recognized by
TLR3 and TLR9 and they induce production of type I interferon [56, 57]. Additionally, we
included an adjuvant to help enhance immunogenicity even more. Gardiquimod VacciGrade
(Invivogen) is a TLR7 agonist. Activation of TLR7 enhances recruitment of macrophages and
dendritic cells, which are the cells that present antigen to CD8 T cells to induce CTLs [58]. We
believe including this compound will enhance CTL induction in our mouse experiments.
Determining ZIKV and DENV NS3 Epitopes for Elispot
The T cell repertoire is developed largely through T cell-MHC interactions. T cells use
their T cell receptor (TCR) to detect antigen presented in the context of MHC molecules on the
surface of antigen presenting cells (APCs). Both types of T cells recognize different MHC
molecules. CD4+ T cells bind to MHCII, while CD8+ T cells bind to MHCI. These interactions
and antigen recognition process dictate the fate and specificity of a particular T cell. With respect
to this vaccine, our goal is to induce DENV- and ZIKV-specific CTLs (CD8+ T cells). There are
multiple methods to assess for virus-specific T cells. One way is via chromium release assay.
This older method uses radioactive Chromium 51 to label target cells. Target cells are incubated
with peptide and are then pulsed with antigen-specific CD8+ T cells. If T cells are specific for the
presented peptide, target cells will be lysed and release the intracellular chromium, which can be
quantified to gauge the number of antigen-specific CTLs.
While this method is effective, other methods have become more common to quantify
such cells, like Elispot assays. This enzyme-linked immune absorbent spot assay was initially
developed in 1983, and it focuses on measuring cytokine secretion from cells. Briefly, a plate is
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coated with a capture Ab for a specific cytokine. Next, cells and stimuli are added and incubate
for a period of time to produce and secrete said cytokine. Then, cells and stimuli are washed off,
and a detection Ab is added to bind the secreted cytokine. This Ab is reactive against a different
epitope than the capture Ab. After this, an enzyme-conjugated secondary Ab is added to wells.
Finally, the respective enzyme substrate is added to facilitate spot development. Each spot
indicates one cytokine-secreting cell. The Elispot is similar to an ELISA (enzyme-linked
immunosorbent assay) in that both methods identify secreted cytokines. However, where the two
differ is that an Elispot quantitatively measures the number of cytokine-secreting cells, while an
ELISA measures total cytokine concentration within the well. Since our goal is to induce virusspecific CTLs, we are more interested in the total number of peptide-specific cells rather than
total protein concentration. Therefore, the Elispot assay better suits our needs for this project.
When it came time to decide which ZIKV and DENV NS3 epitopes to use for mouse
experiments, we discovered there is a limited pool of known murine CTL epitopes. Back in
1996, the Ennis group isolated splenocytes from DENV2-vaccinated mice, stimulated them again
with DENV2, and isolated individual clones by limiting dilution. Then, each clone was assessed
for its ability to lyse DENV2-infected P815 target cells. Ultimately, they discovered one of their
CD8+ clones lysed target cells when stimulated with the peptide ARGYISTRVEMGEAA [59].
Furthermore in 2011, the Alves group immunized mice with a DENV2 NS3 construct. Via
Elispot, they showed that the epitope GYISTRVEM induced IFN-g production in splenocytes
from vaccinated Balb/c mice [60]. This peptide has been confirmed as a CTL epitope for
DENV2 and DENV4, and was also used in a ZIKV CTL-detection experiment by a former
graduate student. Additionally, a very similar epitope GYISTRVGM has been identified as a
DENV1 and DENV3 CTL epitope [41]. To ensure we had not missed any known epitopes, we
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also explored the Immune Epitope Database website (iedb.org) for known NS3 mouse epitopes
for all five viruses. We did not find any other confirmed epitopes from in vivo experiments. Due
to the above factors, we felt these two NS3 epitopes were the best choices for our initial
vaccination experiment.
While it is beneficial we can use these known NS3 epitopes for an Elispot, there is one
significant issue to note with these peptides: they are shared across multiple viruses. The epitope
GYISTRVEM is present in ZIKV, DENV2, and DENV4 NS3, while the epitope GYISTRVGM
is present in DENV1 and DENV3 NS3. Ideally, we would like to confidently show that our P1
and P2 constructs induce anti-viral CTLs against all five viruses. If we use a peptide sequence
that is shared across multiple viruses like the two above (i.e. GYISTRVEM), we cannot discern
which virus is responsible for the observed cytokine response (i.e. whether we induced just
DENV2-specific CTLs, just DENV4-specific CTLs, or both). Therefore, it makes more sense to
use virus-specific epitopes in subsequent Elispot experiments to individually assess whether we
induce CTLs against all five viruses. However as mentioned previously, there is a notable lack of
murine NS3 epitopes for ZIKV and DENV1-4. Luckily, CTL epitope prediction software is
available to help predict which NS3 peptides may be CTL epitopes for these viruses. Although
not definitive, this kind of technology provides us with a good starting point for identifying
virus-specific ZIKV and DENV1-4 NS3 CTL epitopes. We used NetCTLPan
(http://www.cbs.dtu.dk/services/NetCTLpan/) to predict H2-Kd epitopes for Balb/c mice for our
five viruses. Peptides with the highest likelihood of binding to MHCI were identified and used
for our second Elispot experiment. The peptides were as follows: Peptide 28 from the DENV1
array (TYVSAIAQA epitope), Peptide 74 from the DENV2 array (SPGTSGSPI epitope),
Peptide 30 from the DENV3 array (IFQTTTGEI epitope), and Peptide 46 from the DENV4 array
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(CHATFTTRL epitope). Since previous experiments from the lab show that our rearrangement
of NS3 induced ZIKV-specific CTLs, this experiment focused on discerning whether our
constructs induced CTLs for the four DENV serotypes.
Elispot to Detect Virus-Specific Splenocytes
Prior to animal sacrifice and spleen collection, the respective DENV-ZIKV NS3 peptides
and positive controls were prepared. For our first animal experiment, 0.5ug or 1ug of each
peptide (GYISTRVEM or GYISTRVGM) was prepared in 100uL serum-free media for each
well. Peptides or positive stimuli (Concanavalin A) were added to wells (Mabtech plates), and
then splenocytes were collected. Splenocytes were collected by crushing spleens between glass
slides over a cell culture dish containing RPMI-1640. Cells were spun down at 1250rpm for 5
min. Supernatant was dumped, and 1mL ACK lysis buffer was added per spleen to lyse red
blood cells. After 1 min at RT, 10 mL RPMI-1640 was added to each tube to neutralize lysis
buffer. Cells were pelleted again and resuspended in 10mL media before counting and seeding at
a density of 200,000 cells/well. We stimulated cells overnight with peptide or positive control for
approximately 18 hrs. The next morning, wells dumped and the Elispot plates were washed 5x
with 200uL sterile PBS per well. Detection antibody was diluted to 0.5ug/mL (TNF-a) or
1ug/mL (IFN-g and IL-2) in PBS containing 0.5% FBS. 100uL of this was added per well and
incubated at RT for 2 hrs and then washed. Streptavidin-ALP was diluted 1:1000 in PBS-0.5%
FBS. 100uL was added per well, and this was incubated at RT for 1 hr. Plates were washed as
described above. The ready-to-use substrate solution (BCIP/NBT-plus) was passed through a
45um filter, and 100uL was added per well to develop spots for about 15-20 minutes. Plates were
washed with tap water and dried completely before we counted spots.
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Results for our first vaccination experiment are in Figure 3. The two tested peptides do
not seem to induce any significant IFN-g or IL-2 production in the splenocytes of vaccinated
mice. However, there seems to be some slight induction of TNF-a, particularly with the VEM
peptide, which contains the sequence found in ZIKV, DENV2, and DENV4 NS3. This is
something we expect, since multiple groups have previously identified this as a CTL epitope for
these viruses [41]. This is the only experimental condition that achieved statistical significance (p
= 0.0158 for 1ug of peptide). While we observed some increased TNF-a production in the
context of the VGM peptide, it was not statistically significant.
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Figure 3. Elispot Counts from Mice Vaccinated with Ub/NS3 ZIKV-DENV Constructs. 46wk old female Balb/c mice were injected on Day 0 with either PBS or 5ug P1 + 5ug P2 + 20ug
Gardiquimod adjuvant. Mice were boosted with the same compounds at two weeks (Day 14) and
collected at four weeks post initial injection (Day 28). Splenocytes were collected and seeded at
200,000 cells/well. Cells were stimulated with either media (cells only), one of two peptides
overnight (GYISTRVEM = “VEM” or GYISTRVGM = “VGM”), or Con A (positive control).
The next morning, cells and stimulation mixtures were dumped, and Elispot plates were stained
using HRP-conjugated antibodies to assess for production of IFN-g, TNFa, and IL-2 (CTLspecific cytokines). The only condition with a significant p-value (<0.05) is for TNFa production
from vaccinated mice treated with 1ug peptide (indicated in orange text).
There are two main reasons why we may not observe as large an induction of these
cytokines like we expect. First, we may not have administered enough DNA per mouse. Past
experiments from our lab administered 10ug of Ub/NS3 ZIKV plasmid to each mouse, while in
this case, mice received 5ug each of P1 and P2 for a total of 10ug DNA. Subsequent vaccination
experiment in the future will administer 10ug of each plasmid to our mice. Second, we have an
incredibly small sample size, with only 3 mice per group. Due to this size, we have a limited
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pool of mice that may not accurately represent the full scope of virus-specific CTLs induced by
our constructs. We plan to increase total mouse numbers in subsequent vaccination experiments.
For our second vaccination experiment, we used 4-6wk old female and male Balb/c mice
with 6 female and 6 male per group. Experimental groups were as follows: PBS only, 20ug
Gardiquimod only, and 10ug P1 + 10ug P2 + 20ug Gardiquimod. All mice received hind
quadriceps injections of 50uL total. Mice were first injected with respective compounds on Day
0, and then boosted with the same compounds three weeks after initial injection (Day 21). Mice
were sacrificed ten days after boost injections (Day 31), and at this point, spleens were collected
to assess the DENV-specific splenocyte response. Only DENV responses were tested since a
former graduate student showed that our Ub/NS3 ZIKV rearrangement induced ZIKV-specific
CTLs. Various DENV-specific peptides were used for splenocyte stimulation: Peptide 28 from
the DENV1 array (TYVSAIAQA epitope), Peptide 74 from the DENV2 array (SPGTSGSPI
epitope), Peptide 30 from the DENV3 array (IFQTTTGEI epitope), and Peptide 46 from the
DENV4 array (CHATFTTRL epitope). 1ug of peptides or PMA/ionomycin were added to wells
in 100uL RPMI-1640. Splenocytes were collected, seeded, and stimulated as previously
described in our first Elispot assay. Plates were incubated at 37oC overnight (approximately
18hrs). The following morning, wells were dumped washed 3x with Wash Buffer (1x PBS +
0.05% Tween-20). Biotinylated detection Ab was diluted 1:250 in 100uL RPMI-1640 and added
to wells to incubate for 2hrs at RT. This solution was discarded, and wells were washed 3x with
200uL Wash Buffer. Streptavidin-HRP secondary Abs were diluted 1:250 in 100uL RPMI and
incubated for 1hr at RT. Secondary Abs were discarded and wells were washed 2x with PBS. To
develop wells, 30uL of TMB substrate (Sigma) was added to each well. Wells developed for
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approximately 5-15 minutes. Plates were washed in tap water are dried overnight before spots
were counted.
Sadly, our plates yielded no spots in any experimental conditions, including the positive
controls. Therefore, we determined there must have been some technical issue with the assay.
Multiple steps could be the cause of this issue, such as the Ab-coating process, ineffective
staining with the primary Ab, or ineffective staining with the secondary Ab. We expect that
splenocytes from vaccinated mice would display significant secretion of IFN-g and TNFa upon
stimulation with any of the four of our DENV peptides. While the assay did not perform as
expected, we plan to repeat this in the near future and use a ZIKV-specific peptide in the Elispot
as well to additionally assess induction of ZIKV-specific CTLs.
Discussion
The goal of these experiments was to demonstrate that our Ub/NS3 constructs induce
DENV- and ZIKV-specific CTLs in mice. In our first Elispot experiment, we showed that
splenocytes from vaccinated mice show increased TNFa production when stimulated with the
ZIKV-DENV2-DENV4-specific peptide GYISTRVEM. This same peptide did not induce
significant induction of IFN-g or IL-2. Moreover, our GYISTRVGM peptide did not induce
production of any of these three CTL cytokines. By adding the ubiquitin monomer and coadministering Gardiquimod adjuvant at vaccination, we hoped to induce more striking numbers
of virus-specific CTLs. Since the peptides in the first Elispot were shared across multiple viruses,
we aimed to find virus-specific peptides we could use to individually assess CTL induction for
all five viruses. Unfortunately, there were no experimentally determined virus-specific CTL
epitopes we could use. Instead, we utilized CTL prediction software to predict which peptides in
NS3 would most likely be presented by mouse MHCI (H2-Kd for Balb/c) and therefore, could
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potentially induce virus-specific CTLs. When performing this second experiment, we doubled
the total DNA administered to our mice (10ug each of P1 and P2 vs 5ug each), increased our
overall sample size (6 female and 6 male per group vs only 3 female), and added an adjuvantonly group as another negative control. Mice were vaccinated on Day 0, boosted at Day 21, and
sacrificed on Day 35, at which point virus-specific CTL responses were assessed. Unfortunately,
this assay experienced technical issues and did not yield any viable results. We hope to repeat
this experiment in the near future. Not only will this larger sample size give us a better indication
of the true CTL repertoires induced by our constructs, but it will also demonstrate whether any of
our five predicted flavivirus epitopes can actually be used to successfully assess for the presence
of ZIKV- or DENV-specific CTLs.

CHAPTER 5
CONCLUSIONS
ZIKV and DENV are still prevalent viruses that infect many people in various parts of
the world. The need for a vaccine is already great in that respect, but it is even greater when one
considers how one virus can enhance infection of the other through ADE. Therefore, a new
vaccine strategy must be implemented. While there are many vaccines currently in clinical trials,
these vaccines primarily induce neutralizing antibodies rather than CTLs. A CTL-based approach
appears to be the most promising design strategy, given the evident cross-reactivity of flavivirus
antibodies. Our data show that plasmids encoding for rearranged, ubiquitinated NS3 sequences
are readily expressed. They appear to be targeted to the proteasome where they have the potential
to generate MHCI epitopes and subsequently induce CTLs. In vivo data suggests this vaccine can
upregulate anti-virus CTL populations, albeit to a modest degree. Further in vivo vaccination
studies and Elispot assays must be performed to further assess for CTL induction. Ultimately, the
ability of this DNA-based vaccine to protect against DENV and/or ZIKV challenge in vivo will
help push this vaccine forward as a viable option for clinical trials.
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